With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...

On a quest to bring its multiple myeloma antibody-drug conjugate Blenrep back to the U.S. | Members of the FDA's Oncologic ...

UK-listed pharmaceutical company plans to bring four more speciality medicines to late-stage clinical trials this year ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

GSK plc GSK reported second-quarter 2025 core earnings of $1.23 per American depositary share (ADS), which beat the Zacks ...

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage ...

GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and immune-inflammation diseases like lupus. Specialty Medicines now represents ...

The FDA’s Oncologic Drugs Advisory Committee has voted against the benefit/risk profile of GSK’s Blenrep just days before the drug’s PDUFA date.

GSK reported 4% year-on-year earnings growth (at constant currency) and core operating profit margin of 33.7%, or 30 basis points better than the same period last year. This was driven by strong ...

In 2025, GSK expects to launch five new products/line extensions, including Blenrep, depemokimab (severe asthma and CRSwNP), Nucala for COPD, Penmenvy and Blujepa. Of these, Penmenvy, Blujepa and ...

Blenrep combo nearly tripled PFS to 36.6 months vs 13.4 months in DREAMM-7. Blenrep cut risk of death by 42% vs comparator in DREAMM-7 at 39.4-month median follow-up. Up Next: Get 5 Dark Horse ...